<i id='021777069F'><strike id='021777069F'><tt id='021777069F'><pre id='021777069F'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Alkermes shareholders re 
Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S. 
Biden outlines 'new path' to provide student loan relief after Supreme Court rejection 
Illumina board agrees to spin off Grail, as divestment plans proceed 
Activists slam private health insurers over coverage restrictions 
Suspects arrested after 3 women attacked on Manhattan's West Side: Police 
Hepatitis C has a cure — but many Americans still lack access to it 
Sutter Health’s antitrust win overturned by appeals court 
23andMe had bad news about my health. I wish a person had delivered it
Sutter Health’s antitrust win overturned by appeals court 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
Reframing the conversation around gain
Hepatitis C has a cure — but many Americans still lack access to it 
Stopping antidepressants leads to symptoms for 1 in 6 patients 
The cancer drug shortage isn’t new — and neither are the solutions 
